{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T01:40:04Z","timestamp":1750902004678,"version":"3.41.0"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>The review presents the recent rapid expansion of therapeutical options in spondyloarthritis. Additionally, it focuses on the importance of additional questions raised by the growing therapeutic possibilities related to the optimal use of these drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>The emergence of new treatment options opens new avenues and opportunities for treating patients with nonresponse, contraindications, or intolerance for classic drugs. However, it becomes more relevant than ever to define not only drugs and treatment options but also treatment strategies. We address current literature and remaining questions on strategies such as early intervention, combination treatment, personalized medicine, and treat-to-target.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Not only the treatment as such, but also the treatment strategy is crucial to reveal the full therapeutic potential and benefit for patients. Whereas cautious but crucial steps have been taken in the last years to explore these aspects, related to timing and sequence of treatment (including combination treatments), stratified medicine approaches, and treat-to-target strategies, it is now time for full-scale investment in prospective strategy trials.<\/jats:p><\/jats:sec>","DOI":"10.1097\/bor.0000000000000457","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T22:21:49Z","timestamp":1507242109000},"page":"79-86","source":"Crossref","is-referenced-by-count":6,"title":["New treatment paradigms in spondyloarthritis"],"prefix":"10.1097","volume":"30","author":[{"given":"Leonieke J.J.","family":"van Mens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marleen G.H.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique L.P.","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"(Suppl 2)","key":"R1-20230829","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1136\/ard.2004.033654","article-title":"Seronegative spondyloarthropathies: to lump or split?","volume":"64","author":"Nash","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","article-title":"Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis; results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2016-eular.2952","article-title":"OPO108 Bimekizumab, a monoclonal antibody that inhibits both IL-17A and IL-17F, produces a profound response in both skin and joints: results of an early-phase, proof-of-concept study in psoriatic arthritis","volume":"75","author":"Glatt","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2017-eular.1164","article-title":"OPO218 efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study","volume":"76","author":"Deodhar","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00296-016-3635-8","article-title":"Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?","volume":"37","author":"Keat","year":"2017","journal-title":"Rheumatol Int"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R21-20230829","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial, for the MEASURE 1 study group","author":"Baraliakos","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","article-title":"Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial","volume":"388","author":"Bijlsma","year":"2016","journal-title":"Lancet"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/annrheumdis-2012-202245","article-title":"Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis","volume":"72","author":"Paramarta","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1002\/art.21426","article-title":"Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies","volume":"52","author":"Kruithof","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/annrheumdis-2016-210775","article-title":"Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study","volume":"76","author":"Carron","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.2007.075309","article-title":"Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study","volume":"67","author":"Sieper","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","article-title":"Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"e000389","DOI":"10.1136\/rmdopen-2016-000389","article-title":"Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort","volume":"3","author":"Abawi","year":"2017","journal-title":"RMD Open"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3899\/jrheum.101117","article-title":"Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire: a report from the GRAPPA 2009 annual meeting","volume":"38","author":"Chandran","year":"2011","journal-title":"J Rheumatol"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2007.04.001","article-title":"The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool","volume":"57","author":"Husni","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R38-20230829","first-page":"469","article-title":"Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the psoriasis epidemiology screening tool (PEST) questionnaire","volume":"27","author":"Ibrahim","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","article-title":"The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study","volume":"74","author":"Lie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/art.39691","article-title":"The Effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial spondyloarthritis","volume":"68","author":"Nissen","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/art.39772","article-title":"Effect of comedication with conventional synthetic disease-modifying antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with spondyloarthritis: a prospective cohort study","volume":"68","author":"Sepriano","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.23167","article-title":"Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment","volume":"58","author":"Breban","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3899\/jrheum.110295","article-title":"Combination biologic treatment of refractory psoriasis and psoriatic arthritis","volume":"39","author":"Cuchacovich","year":"2012","journal-title":"J Rheumatol"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/ard.2003.018549","article-title":"Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy","volume":"64","author":"Kruithof","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B","article-title":"Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study","volume":"44","author":"Baeten","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+CD3+CD4-CD8-entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4049\/jimmunol.1003986","article-title":"IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass","volume":"187","author":"Adamopoulos","year":"2011","journal-title":"J Immunol"},{"key":"R55-20230829","first-page":"145","article-title":"A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial: commentary","volume":"8","author":"Huizinga","year":"2010","journal-title":"Int J Adv Rheumatol"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis: results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"R59-20230829","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"R61-20230829","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"R63-20230829","first-page":"27","article-title":"A human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"13","author":"Balzola","year":"2012","journal-title":"Inflamm Bowel Dis Monit"},{"key":"R64-20230829","first-page":"67","article-title":"Update on the use of systemic biologic agents in the treatment of noninfectious uveitis","volume":"8","author":"Pasadhika","year":"2014","journal-title":"Biologics"},{"key":"R65-20230829","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R66-20230829","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archophthalmol.2009.141","article-title":"Infliximab therapy for refractory uveitis: 2-year results of a prospective trial","volume":"127","author":"Suhler","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R67-20230829","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"R68-20230829","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R69-20230829","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"(Suppl 2)","key":"R70-20230829","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/annrheumdis-2015-eular.3382","article-title":"OPO202 anti-IL-17A treatment blocks inflammation and new bone formation in experimental spondyloarthritis in HLA-B27 transgenic rats","volume":"74","author":"Van Tok","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R71-20230829","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R72-20230829","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R73-20230829","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.38323","article-title":"Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?","volume":"66","author":"Solomon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R74-20230829","first-page":"1251","article-title":"New GRAPPA and EULAR recommendations for the management of psoriatic arthritis","volume":"56","author":"Coates","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R75-20230829","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R76-20230829","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"R77-20230829","article-title":"The cost-effectiveness of tight control of inflammation in early psoriatic arthritis: Economic analysis of the TICOPA trial","author":"O\u2019Dwyer","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201801000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:59:50Z","timestamp":1750899590000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201801000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000457","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"type":"print","value":"1040-8711"},{"type":"electronic","value":"1531-6963"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}